Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964404 · ClinicalTrials.gov registry record · Phase 1
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT01964404: Completed Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT01964404 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 263 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01964404, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in these patients and, thereby, provide evidence in support of the role of cannabis as a "self-medication" agent for them.
Primary Outcome
Activation of the Brain Reward Circuit (particularly the nucleus accumbens) in anticipation of monetary reward. The 'Measure' is a mean of the Fisher-Z transform of the inter-regional correlation measured for each participant between the nucleus accumbens and anterior cingulate cortex. The Fisher-transformation creates a normally distributed correlation value for statistical analyses assessing between group differences. A Fisher-Z transform of '0' represents a value of '0' for the estimated corr
Interventions
- DRUG Placebo
- DRUG Dronabinol
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-09-18 |
| Phase | Phase 1 |
What the finished NCT01964404 record still lists
NCT01964404 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01964404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01964404 about?
NCT01964404 is a clinical study titled "Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?". In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fac...
What is the current status of trial NCT01964404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2014-07. Estimated completion is 2021-09-18.
What interventions are being tested in trial NCT01964404?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT01964404?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01964404's enrollment target sits among peer trials
263 158th of 2000 higher than 1,842 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia